Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Down 41.5% in July

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the recipient of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 13,660,000 shares, adropof41.5% from the July 15th total of 23,360,000 shares. Approximately6.1% of the shares of the company are short sold. Based on an average trading volume of 5,700,000 shares, the days-to-cover ratio is presently 2.4 days. Based on an average trading volume of 5,700,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately6.1% of the shares of the company are short sold.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 21,793 shares during the last quarter. R Squared Ltd bought a new position in Sangamo Therapeutics during the 2nd quarter worth $28,000. Captrust Financial Advisors acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter worth $30,000. LPL Financial LLC lifted its holdings in shares of Sangamo Therapeutics by 113.5% during the fourth quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 16,498 shares in the last quarter. Finally, Cerity Partners LLC boosted its position in shares of Sangamo Therapeutics by 439.2% in the first quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 44,800 shares during the period. Institutional investors and hedge funds own 56.93% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, June 24th. Finally, Barclays lowered their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Sangamo Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $4.50.

Sangamo Therapeutics Price Performance

Shares of SGMO opened at $0.58 on Monday. The company's 50-day moving average is $0.52 and its 200-day moving average is $0.70. The firm has a market capitalization of $174.99 million, a PE ratio of -2.00 and a beta of 1.18. Sangamo Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The company had revenue of $18.31 million during the quarter, compared to analyst estimates of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. Analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.